Funding for this research was provided by:
National Ataxia Foundation
EU Joint Programme – Neurodegenerative Disease Research
Richard Chin and Lily Lock Machado Joseph Disease Research Fund
European Regional Development Fund through the Regional Operational Program Center 2020 (ViraVector (CENTRO-01-0145-FEDER-022095))
Received: 9 November 2019
Accepted: 14 March 2020
First Online: 9 April 2020
Ethics approval and consent to participate
: All experimental procedures with animals were performed in accordance with the European Union Directive 86/609/EEC for the care and use of laboratory animals. This study is part of a research project which was approved by the Center for Neuroscience and Cell Biology ethics committee (ORBEA_66_2015_/22062015) and the Portuguese Authority responsible for the regulation of animal experimentation, Direcção Geral da Agricultura e Veterinária (DGAV 0421/000/000/2015).
: Not applicable.
: Luís Pereira de Almeida reports grants from BioBlast Pharma during the conduct of the study. Hagar Greif was an employee at Bioblast Pharma during the course of the work. All the other authors have nothing to disclose.